Fraser
M&a;A advisory and investment firm, partnering with leaders in Europe’s B2B technology sectors to unlock next levels of growth &a; success.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Fraser Information
Geographic Data
Address: 33 Street James's Square
City: London
State: england
Zip: SW1Y 4JS
Country: GB
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Facebook
Linkedin
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Fraser is a dedicated M&a;A advisory and investment firm, partnering with leaders in Europe’s B2B technology sectors to unlock next levels of growth &a; success. Based in Berlin, London and Chicago, we advise entrepreneurs, senior management and boards on their most important strategic decisions and transactions. Alongside our clients and partners, we also invest into selected opportunities. Since 2005, we have completed over $1BN of transactions, incl. ADTECH AG (acquired by AOL), 3GNet GmbH (acquired by iCrossing and subsequently sold to Hearst), UDG (backed with $100M+ by EQT and recently merged with PIA Performance Interactive Alliance), nugg.ad AG (acquired by Deutsche Post DHL and then sold to Zalando), Optivo GmbH (acquired by Deutsche Post DHL), explido GmbH (acquired by Dentsu Aegis Network and combined to form explido iProspect), Adglow (acquisition of Glow), Episerver AB (acquisition of Optivo GmbH, backed by Accel-KKR), Tessian (backed by Sequoia), diffferent GmbH (acquired by Syzygy, part of WPP), and m-pathy GmbH (acquired by Verint). For further information or to contact a member of our senior team, please visit: https://www.fraserfinance.com
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2011 | Pole Star | Series B | 4.1M |
| 6/2015 | Lumeon | Series B | 0 |
| 6/2018 | Clinical Genomics Technologies | Series B | - |
| 6/2018 | Tessian | Series A | 13M |
| 6/2015 | Tessian | Pre Seed Round | 340.6k |
| 5/2022 | Therapixel | Series B | 0 |
| 12/2018 | Lumeon | Series C | 0 |
| 6/2017 | Lumeon | Debt Financing | 0 |
| 9/2012 | F2G | Equity | 30M |
| 9/2019 | PathoQuest | Venture Round | 0 |
| 5/2016 | ExThera Medical | Venture Round | - |
| 12/2020 | Spearad | Seed Round | - |
| 5/2018 | PathoQuest | Venture Round | 0 |
| 5/2021 | Incision | Series A | 6.1M |
| 11/2021 | PathoQuest | Series B | 17.4M |
| 12/2020 | Spearad | Seed Round | - |
| 9/2019 | PathoQuest | Venture Round | 0 |
| 12/2018 | Lumeon | Series C | 0 |
| 6/2018 | Tessian | Series A | 0 |
| 6/2018 | Clinical Genomics Technologies | Series B | - |
| 5/2018 | PathoQuest | Venture Round | 0 |
| 6/2017 | Lumeon | Debt Financing | 0 |
| 5/2016 | ExThera Medical | Venture Round | - |
| 6/2015 | Tessian | Pre Seed Round | 0 |
| 6/2015 | Lumeon | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
